All News

back, LBP, spine, AS

Difficult to Manage Axial Spondyloarthritis

d Adela Castro, MD

Studies show that patients with difficult-to-manage axSpA have a higher disease activity; however, the lack of a consensus definition led researchers and clinicians to utilize their own proposed definition, resulting in variability of the characteristics of non-responders.

Read Article
GCA,woman

SELECT-GCA suggests JAKis may be the new kid on the block

d Mrinalini Dey, MD

Clinicians treating giant cell arteritis (GCA) have long had to contend with a disappointingly limited selection of drugs from which to select. A new group of drugs is finally showing promise in the treatment of GCA.

Read Article
Cross-sectional study finds metabolic dysregulation in RA-ILD is indicative of poor prognosis- FGF-21 assoc w. poor survival. Another link btwn CV risk factors, metabolic syndrome & RA? Should we be doing more to manage metabolic risk factors in RA-ILD? Ab0803 #ACR24 @RheumNow

Mrinalini Dey DrMiniDey ( View Tweet)

Stone et al. Phase 3 RCT B-cell depletion with CD19 targeting agent Inebilizumab in IgG4-RD. HR 0.13 (0.06, 0.28) for flare. @RheumNow #ACR24 Abstr#0775 https://t.co/Kd4Xmoc5e6 https://t.co/Al6gOA1F8K

Links:

Richard Conway RichardPAConway ( View Tweet)
Hamroun et al. Meta-analysis of glucocorticoids in pregnancy and breast-feeding. Increase pre-term birth with GCs, adjusted OR 2.24. Dose-dependent effect. Minimal breastmilk transfer. @RheumNow #ACR24 Abstr#0810 https://t.co/H0o9ElsHmc https://t.co/uciFP6UOhF

Links:

Richard Conway RichardPAConway ( View Tweet)
Prof @WalterMaks et al reports the validation of data-driven quantitative MRI cutoffs for a +SIJ MRI perform highly in pts with established axSpA. - Deep fat lesions & sclerosis: high specificity for #axSpA @RheumNow #ACR24 abs821 https://t.co/sSAtTt1GGV

Links:

sheila RHEUMarampa ( View Tweet)
Not just the presence but higher levels of biomarkers predict RA-ILD progression. #ACR24 @RheumNow ABST#0804 https://t.co/5jhBjXDUeY

Links:

Jiha Lee JihaRheum ( View Tweet)
Medication-assisted weight loss has boomed in recent yrs. How does weight loss affect disease activity & PROs in RMDs? ≥5% weight loss, after taking a med, led to better disease activity & QoL Data may inform RCTs to explore effect of these meds in RMDs Ab0845 #ACR24 @RheumNow

Mrinalini Dey DrMiniDey ( View Tweet)

LTE of deucravacitinib trials in psoriasis. Remarkable & frankly surprising (to me) persistence of benefit Very encouraging for patients who start TYKs, looks like those who respond may have prolonged benefit #ACR24 @RheumNow Abstr#0290 #ACRBest https://t.co/kao4vqpPTQ

Links:

Mike Putman EBRheum ( View Tweet)
Don’t miss the “window of opportunity” for aggressive treatment in early RA! with active RA, risk of ILD 6x and RA-related lung disease 4x higher #ACR24 @RheumNow ABST#0802 https://t.co/yxlfInte6A

Links:

Jiha Lee JihaRheum ( View Tweet)
Cannabis in Pain: CBD can help with nociceptive pain THC better for neuropathic, centralized pain Perhaps a role in helping decrease other medications like opiates Clauw 16S18 #ACR24 @RheumNow https://t.co/kaQXrD4GAn

Links:

Eric Dein ericdeinmd ( View Tweet)
How often should #scleroderma #ILD pts have #PFTs? 🤷‍♂️ Data from SENCIS RCT of SSc-ILD 25% worsened FVC by 6/12 Are we UNDER a ordering PFTs in an ILD #SSc population 👇 Because if worsening we would consider a change in background #immunesuppression @RheumNow #ACR24 #678 https://t.co/a9ybO3FwDd

Links:

Janet Pope Janetbirdope ( View Tweet)
Harkins @DrTrishHarkins et al. 1 year outcomes of 65 PMR patients treated in FTC. 32.7% experienced relapse, 28% still on GCs, 21% on tocilizumab. @RheumNow #ACR24 Abstr#0739 https://t.co/uYBYhPqGQE https://t.co/n9x9BDTPKg

Links:

Richard Conway RichardPAConway ( View Tweet)
Abstract #0805 Data from OTIS Registry shows Certolizumab pegol (Cimzia) exposure during pregnancy was not associated with increased risk of major birth defects, structural defects, or adverse pregnancy outcomes. #ACR24 @RheumNow

Akhil Sood MD AkhilSoodMD ( View Tweet)

Does alcohol consumption affect radiographic progression in axSpA? Canadian cohort study over 6 years found greater radiographic progression among alcohol consumers. Still a lot of confounding factors to fully establish an association. Abst#0822 #ACR24 @RheumNow https://t.co/GG0rXq3kjC

Links:

Adela Castro AdelaCastro222 ( View Tweet)
Results from MANDARA- #EGPA pts treated with benralizumab or mepolizumab Eosinophil-targeting biologics rapidly control airway- & non-airway-related manifestations Few pts had worsening of disease that progressed to organ damage over 52W Ab0828 #ACR24 @RheumNow https://t.co/hIn9iyNVWQ

Links:

Mrinalini Dey DrMiniDey ( View Tweet)
#Disparites posters #ACR24 - Analyzed 954 SLE patients - Black and Asian patients had higher severe damage events - Neighborhood disadvantage (ADI) linked to increased severe damage - Older age and comorbidities increased damage risk abst#0362 @rhuemnow

Bella Mehta bella_mehta ( View Tweet)

What's the assoc between RA disease activity & ILD? Results @MassGenBrigham show early active RA is assoc with ➡️6x incr risk of #ILD ➡️4x incr risk of RA-related lung disease Early DMARDs are vital to reduce articular & extra-articular manifestations! Ab0802 #ACR24 @RheumNow

Mrinalini Dey DrMiniDey ( View Tweet)

RheumNow’s expanded coverage of the #ACR24 meeting is sponsored in part by Novartis. All content is chosen by RheumNow & its faculty.

Dr. John Cush RheumNow ( View Tweet)

Disparities posters #ACR24 - Analyzed 10,604 SLE patients - 18.7% in the lowest SES group experienced functional status decline vs. 12.5% in the highest SES group - African American patients and Greater neighborhood deprivation did worse #ACR24 abst#0190 @RheumNow

Bella Mehta bella_mehta ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×